20/20 Biolabs, Inc. (AIDX) stock
AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3070% below fair value
$0.19−0.00 (-1.01%)
Close on Nov 18, 2026Market cap $2.37MP/E –Yield –
20/20 Biolabs gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2025 it was $604.54K, up 67.8% from the year before.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $604.54K | +67.8% |
| FY2024 | Dec 31, 2024 | $360.31K | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $304.73K | – |
| Q1 FY2026 | Mar 31, 2026 | $62.88K | – |
| Q2 FY2025 | Jun 30, 2025 | $163.26K | – |
| Q1 FY2025 | Mar 31, 2025 | $165.80K | – |
See a number that looks wrong?